Intellia Doses First Patient in Phase 3 Trial of Potential Treatment for Hereditary Angioedema

MT NewswiresJan 22 10:42 ET

Express News | Intellia Therapeutics Inc - Expects to Complete Enrollment in Phase 3 Study by H2 2025

ReutersJan 22 07:30 ET

Express News | Intellia Therapeutics Announces First Patient Dosed in the Haelo Phase 3 Study of Ntla-2002, an Investigational in Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

ReutersJan 22 07:30 ET

Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policies

BenzingaJan 22 04:47 ET

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases

BenzingaJan 22 01:44 ET

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

Intellia TherapeuticsJan 22 00:00 ET